Neuronal markers are expressed in human gliomas and NSE knockdown sensitizes glioblastoma cells to radiotherapy and temozolomide

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Yan, Tao ^a,b,c   Skaftnesmo, Kai O ^b   Leiss, Lina ^b   Sleire, Linda ^b   Wang, Jian ^b,c   Li, Xingang ^a,c   Enger, Per T ^b,d  

^a SHANDONG UNIVERSITY   (China)

^b UNIVERSITY OF BERGEN   (Norway)

^c SHANDONG UNIVERSITY   (China)

^d HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BETA TUBULIN; CLASS III BETA TUBULIN; IMATINIB; MICROTUBULE ASSOCIATED PROTEIN 2; NEUROFILAMENT PROTEIN; NEURON SPECIFIC ENOLASE; PROCARBAZINE; SMALL INTERFERING RNA; TEMOZOLOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG; ALKYLATING AGENT; DACARBAZINE; DRUG DERIVATIVE; ENOLASE; MAP2 PROTEIN, HUMAN; MICROTUBULE ASSOCIATED PROTEIN; TUBULIN;

ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL HYPOXIA; CELL MIGRATION; CELL VIABILITY; CELLULAR STRESS RESPONSE; CHEMOSENSITIZATION; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; GLIOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; RADIOSENSITIZATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR BIOPSY; UPREGULATION; WESTERN BLOTTING; BIOPSY; BRAIN TUMOR; CELL MOTION; DRUG EFFECT; GENE INACTIVATION; GLIOMA; IMPEDANCE; METABOLISM; MIDDLE AGED; RADIATION EXPOSURE; TUMOR CELL LINE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; BIOPSY; BLOTTING, WESTERN; BRAIN NEOPLASMS; CELL HYPOXIA; CELL LINE, TUMOR; CELL MOVEMENT; DACARBAZINE; ELECTRIC IMPEDANCE; FEMALE; GENE KNOCKOUT TECHNIQUES; GLIOBLASTOMA; GLIOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; NEUROFILAMENT PROTEINS; PHOSPHOPYRUVATE HYDRATASE; REAL-TIME POLYMERASE CHAIN REACTION; TUBULIN; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 83655197799     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-524     Document Type: Article

References (36)

1. Eng LF. Glial fibrillary acidic protein (GFAP): the major protein of glial intermediate filaments in differentiated astrocytes. J Neuroimmunol 1985, 8(4-6):203-214.
2. Linskey ME, Gilbert MR. Glial differentiation: a review with implications for new directions in neuro-oncology. Neurosurgery 1995, 36(1):1-21. discussion 21-22, 10.1227/00006123-199501000-00001, 7708144.
3. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9(3):157-173. 10.1016/j.ccr.2006.02.019, 16530701.
4. Prestegarden L, Enger PO. Cancer stem cells in the central nervous system--a critical review. Cancer Res 2010, 70(21):8255-8258. 10.1158/0008-5472.CAN-10-1592, 20959482.
5. Donev K, Scheithauer BW, Rodriguez FJ, Jenkins S. Expression of diagnostic neuronal markers and outcome in glioblastoma. Neuropathol Appl Neurobiol 2010, 36(5):411-421. 10.1111/j.1365-2990.2010.01078.x, 20298476.
6. Varlet P, Soni D, Miquel C, Roux FX, Meder JF, Chneiweiss H, Daumas-Duport C. New variants of malignant glioneuronal tumors: a clinicopathological study of 40 cases. Neurosurgery 2004, 55(6):1377-1391. discussion 1391-1372.
7. Prestegarden L, Svendsen A, Wang J, Sleire L, Skaftnesmo KO, Bjerkvig R, Yan T, Askland L, Persson A, Sakariassen P, et al. Glioma cell populations grouped by different cell type markers drive brain tumor growth. Cancer Res 2010, 70(11):4274-4279. 10.1158/0008-5472.CAN-09-3904, 20460538.
8. Katsetos CD, Del Valle L, Geddes JF, Assimakopoulou M, Legido A, Boyd JC, Balin B, Parikh NA, Maraziotis T, de Chadarevian JP, et al. Aberrant localization of the neuronal class III beta-tubulin in astrocytomas. Arch Pathol Lab Med 2001, 125(5):613-624.
9. Wharton SB, Chan KK, Whittle IR. Microtubule-associated protein 2 (MAP-2) is expressed in low and high grade diffuse astrocytomas. J Clin Neurosci 2002, 9(2):165-169. 10.1054/jocn.2001.1055, 11922706.
10. Giannini C, Scheithauer BW, Lopes MB, Hirose T, Kros JM, VandenBerg SR. Immunophenotype of pleomorphic xanthoastrocytoma. Am J Surg Pathol 2002, 26(4):479-485. 10.1097/00000478-200204000-00010, 11914626.
11. Perry A, Scheithauer BW, Macaulay RJ, Raffel C, Roth KA, Kros JM. Oligodendrogliomas with neurocytic differentiation. A report of 4 cases with diagnostic and histogenetic implications. J Neuropathol Exp Neurol 2002, 61(11):947-955.
12. Rodriguez FJ, Scheithauer BW, Robbins PD, Burger PC, Hessler RB, Perry A, Abell-Aleff PC, Mierau GW. Ependymomas with neuronal differentiation: a morphologic and immunohistochemical spectrum. Acta Neuropathol 2007, 113(3):313-324. 10.1007/s00401-006-0153-x, 17061076.
13. Tlhyama T, Lee VM, Trojanowski JQ. Co-expression of low molecular weight neurofilament protein and glial fibrillary acidic protein in established human glioma cell lines. Am J Pathol 1993, 142(3):883-892. 1886782, 8456947.
14. Akslen LA, Andersen KJ, Bjerkvig R. Characteristics of human and rat glioma cells grown in a defined medium. Anticancer Res 1988, 8(4):797-803.
15. Bjerkvig R, Tonnesen A, Laerum OD, Backlund EO. Multicellular tumor spheroids from human gliomas maintained in organ culture. J Neurosurg 1990, 72(3):463-475. 10.3171/jns.1990.72.3.0463, 2406382.
16. Sakariassen PO, Prestegarden L, Wang J, Skaftnesmo KO, Mahesparan R, Molthoff C, Sminia P, Sundlisaeter E, Misra A, Tysnes BB, et al. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 2006, 103(44):16466-16471. 10.1073/pnas.0607668103, 1618812, 17056721.
17. Malich G, Markovic B, Winder C. The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines. Toxicology 1997, 124(3):179-192. 10.1016/S0300-483X(97)00151-0, 9482120.
18. Katsetos CD, Dráberová E, Legido A, Dumontet C, Dráber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol 2009, 221(3):505-513. 10.1002/jcp.21870, 19650075.
19. Marangos PJ, Schmechel DE, Parma AM, Goodwin FK. Developmental profile of neuron-specific (NSE) and non-neuronal (NNE) enolase. Brain Res 1980, 190(1):185-193. 10.1016/0006-8993(80)91168-3, 6769532.
20. Watanabe M, Nagamine T, Sakimura K, Takahashi Y, Kondo H. Developmental study of the gene expression for alpha and gamma subunits of enolase in the rat brain by in situ hybridization histochemistry. J Comp Neurol 1993, 327(3):350-358. 10.1002/cne.903270304, 8440770.
21. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis?. Nat Rev Cancer 2004, 4(11):891-899. 10.1038/nrc1478, 15516961.
22. Vinores SA, Bonnin JM, Rubinstein LJ, Marangos PJ. Immunohistochemical demonstration of neuron-specific enolase in neoplasms of the CNS and other tissues. Arch Pathol Lab Med 1984, 108(7):536-540.
23. Vinores SA, Marangos PJ, Bonnin JM, Rubinstein LJ. Immunoradiometric and immunohistochemical demonstration of neuron-specific enolase in experimental rat gliomas. Cancer Res 1984, 44(6):2595-2599.
24. Hattori T, Takei N, Mizuno Y, Kato K, Kohsaka S. Neurotrophic and neuroprotective effects of neuron-specific enolase on cultured neurons from embryonic rat brain. Neurosci Res 1995, 21(3):191-198. 10.1016/0168-0102(94)00849-B, 7753500.
25. Kuramitsu M, Sawa H, Takeshita I, Iwaki T, Kato K. Neuron-specific gamma-enolase derived from human glioma. Neurochem Pathol 1986, 4(2):89-105.
26. Scatena R, Bottoni P, Pontoglio A, Mastrototaro L, Giardina B. Glycolytic enzyme inhibitors in cancer treatment. Expert Opin Investig Drugs 2008, 17(10):1533-1545. 10.1517/13543784.17.10.1533, 18808312.
27. Amberger-Murphy V. Hypoxia helps glioma to fight therapy. Curr Cancer Drug Targets 2009, 9(3):381-390. 10.2174/156800909788166637, 19442057.
28. Hamaguchi T, Iizuka N, Tsunedomi R, Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima M, Tamesa T, et al. Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol 2008, 33(4):725-731.
29. Tsai ST, Chien IH, Shen WH, Kuo YZ, Jin YT, Wong TY, Hsiao JR, Wang HP, Shih NY, Wu LW. ENO1, a potential prognostic head and neck cancer marker, promotes transformation partly via chemokine CCL20 induction. Eur J Cancer 2010, 46(9):1712-1723. 10.1016/j.ejca.2010.03.018, 20435467.
30. Petrovic M, Tomic I, Plavec G, Ilic S, Ilic N, Baskic D. Neuron specific enolase tissue expression as a prognostic factor in advanced non small cell lung cancer. J BUON 2008, 13(1):93-96.
31. Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D. Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol 2003, 34(10):1001-1008. 10.1053/S0046-8177(03)00411-8, 14608533.
32. Berner A, Harvei S, Tretli S, Fossa SD, Nesland JM. Prostatic carcinoma: a multivariate analysis of prognostic factors. Br J Cancer 1994, 69(5):924-930. 10.1038/bjc.1994.179, 1968899, 7514029.
33. Allen FJ, Van Velden DJ, Heyns CF. Are neuroendocrine cells of practical value as an independent prognostic parameter in prostate cancer?. Br J Urol 1995, 75(6):751-754. 10.1111/j.1464-410X.1995.tb07385.x, 7613832.
34. Vos MJ, Postma TJ, Martens F, Uitdehaag BM, Blankenstein MA, Vandertop WP, Slotman BJ, Heimans JJ. Serum levels of S-100B protein and neuron-specific enolase in glioma patients: a pilot study. Anticancer Res 2004, 24(4):2511-2514.
35. Ayoub MS, Baghdadi HM, El-Kholy M. Immunohistochemical detection of laminin-1 and Ki-67 in radicular cysts and keratocystic odontogenic tumors. BMC Clin Pathol 2011, 11:4. 10.1186/1472-6890-11-4, 3056737, 21366912.
36. Katsetos CD, Draberova E, Legido A, Dumontet C, Draber P. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin. J Cell Physiol 2009, 221(3):505-513. 10.1002/jcp.21870, 19650075.